A lot to talk about in June…
ZayaAI introduced a Pathology Laboratory Information System (LIS), addressing integration issues between digital pathology IMS and outdated lab software. The acquisition of Visonex by PreciPoint further indicates market convergence.
PathAI launched two AI products: PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore1™, aimed at single-cell image analysis for biomarker discovery and companion diagnostics.
Roche gained FDA 510(k) clearance for its VENTANA DP 200 scanner, marking rapid growth in the US market amidst increased regulation.
Tempus AI went public, providing digital pathology services and patient data access, competing with vendors like Paige and PathAI through advanced algorithms for IHC and H&E staining.
Imogen Fitt is Senior Market Analyst at Signify Research. During her tenure Imogen has completed studies on digital pathology, LabIT and the use of AI in drug development, expanding Signify Research’s diagnostics and life sciences business coverage.
